Long-term remission of T-cell large granular lymphocyte leukemia associated with rheumatoid arthritis after rituximab therapy

Divi Cornec, Valérie Devauchelle-Pensec, Sandrine Jousse-Joulin, Thierry Marhadour, Valérie Ugo, Christian Berthou, Nathalie Douet-Guilbert and Alain Saraux
Long-term remission of T-cell large granular lymphocyte leukemia associated with rheumatoid arthritis after rituximab therapy

Divi Corneo,1,2,3 Valérie Devauchelle-Pensec,1,2,3 Sandrine Jousse-Joulin,1,2,3 Thierry Marhadour,1 Valérie Ugo,2,3,4 Christian Berthou,2,3,5 Nathalie Douet-Guilbert,2,3,6 and Alain Saraux1,2,3

1Service de Rhumatologie, Centre Hospitalier Régional et Universitaire de Brest, Brest, France; 2Faculté de Médecine et des Sciences de la Santé, Université de Brest, Brest, France; 3Université Européenne de Bretagne, France; 4Laboratoire d’Hématologie, 5Servie d’Hématologie Clinique, and 6Laboratoire de Cytogénétique, Centre Hospitalier Régional et Universitaire de Brest, Brest, France

Key Points

• Rituximab may be a safe and effective therapy in patients with both large granular lymphocyte leukemia and rheumatoid arthritis.
• LGLL in some patients with rheumatoid arthritis may be a reactive manifestation of chronic autoantigen stimulation rather than a true concomitant malignancy.

Introduction

T-cell large granular lymphocyte leukemia (LGLL) is a rare clonal disease often associated with rheumatoid arthritis (RA) and manifests chiefly as neutropenia and recurrent infections. Immunosuppressive agents are the mainstay of treatment, but long-term remissions are rare. We report 2 cases of LGLL in patients with RA successfully treated with rituximab, a monoclonal antibody specific of B cells and approved for treating RA. The first patient experienced a complete LGLL remission that was sustained during the 8-year follow-up after the first rituximab infusion. In the second patient, rituximab therapy was followed by immediate neutropenia recovery and then by marked shrinkage of the LGLL clone 1 year later. The paradoxical efficacy of this specific anti-B-cell drug on a monoclonal T-cell disease suggests that some cases of LGLL may be reactive manifestations of chronic autoantigen stimulation rather than true malignancies. (Blood. 2013;122(9):1583-1586)

Study design

Case 1

A woman born in 1932 was diagnosed in 1998 with erosive rheumatoid factor–positive RA. Subsequent tests were positive for anti-citrullinated protein antibody. Within a few months, severe neutropenia developed (Figure 1), and investigations showed a monotypic T-cell receptor (TCR)ab 3 ’CD3’CD8’ CD16’CD56’CD57’ T-cell LGLL population in the blood and bone marrow. The absolute blood LGLL count was 2.5 Giga (G)/L, representing 50% of total lymphocytes. A TCR-gene rearrangement study detected a monoclonal T-cell receptor gene rearrangement. The patient had profound agranulocytosis revealed by severe stomatitis. In 2004, chronic fever and weight loss developed. Extensive investigations found no evidence of infection, and the RA was quiescent. The cyclosporine was stopped, and weekly granulocyte colony-stimulating factor (G-CSF) injections were started and then changed in 2001 to cyclosporine 2 mg/kg/day combined with weekly granulocyte colony-stimulating factor (G-CSF) injections as the patient had profound agranulocytosis revealed by severe stomatitis. In 2004, chronic fever and weight loss developed. Extensive investigations found no evidence of infection, and the RA was quiescent. The cyclosporine was stopped, and then the neutropenia worsened, requiring daily G-CSF injections. The monoclonal IgM component level increased to 21 g/L, the κ/λ free light-chain ratio increased to 5, and massive κ Bence-Jones proteinuria appeared. Again, histological, cytological, and flow cytometry studies of bone marrow


The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

© 2013 by The American Society of Hematology
showed no signs of B-cell lymphoma. No lymphadenopathy was found by physical examination or computed tomography. Rituximab therapy was started in May 2005 (4 infusions of 375 mg/m² each). The constitutional symptoms resolved rapidly, and the neutrophil blood count increased progressively until normalization after 4 months without further G-CSF injections. The monoclonal IgM component level decreased gradually. Two additional rituximab courses (each consisting of 2 1000-mg infusions) were given in 2008 and 2010 for RA flares. At the last evaluation in May 2013, the neutrophil count was normal at 3.2 G/L, the monoclonal IgM titer was 2.1 g/L, and the blood lymphocyte immunophenotype was normal. The hemoglobin level and platelet count were also normal. No monoclonal T-cell population was detectable by TCR-gene rearrangement study. Thus, the LGLL was in complete remission 8 years after the first rituximab infusion.

Case 2

This man born in 1948 started experiencing inflammatory pain in the hands and feet in March 2011. Neutropenia was first detected in June 2011 (Figure 2). Seropositive erosive RA was diagnosed in November 2011, and low-dose methotrexate and prednisone were started. Three months later, neither the joint disease nor the leukemia was improved. Two 1000-mg rituximab infusions provided a rapid remission of the joint disease accompanied with immediate neutrophil count normalization despite persistence of the monoclonal T-cell population. Six months later, a second rituximab course was given for exacerbation of the joint symptoms. In January 2013, the RA was still in remission despite prednisone discontinuation, neutrophil counts remained normal, and the leukemic cell count was substantially decreased. DAS28, RA disease activity score evaluating 28 joints; MTX, methotrexate.
Hematological investigations disclosed a monoclonal TCR-αβ CD3⁺ CD8⁺ CD16⁻ CD56⁻ CD57⁻ LGL population representing 50% of blood and bone marrow lymphocytes (absolute blood LGL count, 2.1 G/L). TCR-Vβ flow cytometry showed a defective repertoire, and clonality was demonstrated by TCR-gene rearrangement analysis. He had no splanchnic or lymphopenopathy. T-cell LGLL was diagnosed, but the only treatment was a G-CSF injection in September 2011. In November 2011, rheumatoid factor– and anti-citrullinated protein antibody–positive RA was diagnosed. Methotrexate and prednisone were started, but 3 months later the joint symptoms had worsened despite a prednisone dosage increase to 20 mg/d. The neutrophil count returned to normal after the first rituximab infusion and subsequently remained within the normal range. In July 2012, an increase in RA activity prompted a second rituximab course. The total lymphocyte count was normal (2.7 G/L), but the phenotype showed 40% monoclonic CD3⁺ CD8⁺ CD57⁻ cells (absolute LGL count, 1.1 G/L). In January 2013, despite prednisone discontinuation since September 2012, the RA remained in remission. The neutrophil count was 3.6 G/L, and the CD3⁺ CD8⁺ CD57⁻ cells contributed only 13% of the total blood lymphocytes (LGL, 0.4 G/L). The monoclonal clone was still detectable by TCR-gene rearrangement molecular analysis.

**Results and discussion**

To our knowledge, our 2 patients are the first reported cases of successful rituximab therapy in RA-associated T-cell LGLL. The long-term follow-up in the first patient indicates that rituximab can produce a sustained improvement and even complete remission of LGLL. Rituximab was well tolerated in both patients.

Two pathogenic theories have been proposed for T-cell LGLL. The initiating event leading to the monoclonal T-cell proliferation may be an acquired intrinsic molecular defect, such as a mutation. A recent study identified a somatic mutation in the signal transducer and activator of the transcription 3 gene in 31 (40%) of 77 LGLL patients, with a higher proportion (73%) in patients with RA. Such a mutation may cause the development of a monoclonal T-cell population.

Alternatively, the T-cell expansion may be driven by a combination of persistent antigenic stimulation and immunogenetic factors. LGLL cells exhibit the phenotype and genotype of cells subjected to chronic antigen activation, which may initiate clonal transformation. Serial measurements in 71 patients with T-cell LGLL showed that the dominant clonal population contracted or even disappeared over time in 26 (37%) patients, with or without a link to treatment, and was replaced by another clonal population expressing a different Vβ region. These findings suggest that, in some cases, development of the clonal population may be a reactive process unrelated to an intrinsic molecular defect. In RA, the effects of rituximab on the immune system may consist not only in transient B-cell depletion, but also in changes in the microenvironment and cytokine balance capable of impairing LGL clone survival without directly affecting the leukemic LGLs. This mechanism would explain the gradual shrinkage of the monoclonal population in our patients, until complete disappearance after several months in our first patient.

Late-onset neutropenia is a rare and usually transient complication of rituximab therapy in patients with malignant and rheumatic disorders. In some of these patients, an increase in CD3⁺ CD8⁺ CD57⁺ T-cell LGLs in the peripheral blood and bone marrow was described, with no monoclonality by TCR gene analysis.

As illustrated by our first patient, T-cell LGLL is frequently associated with concomitant low-grade B-cell dyscrasias, as monoclonal gammopathy of unknown significance or chronic lymphocytic leukemia, suggesting that a common antigen may drive both T- and B-cell proliferation.

In conclusion, rituximab therapy may be safe and effective in LGLL-related neutropenia in RA patients and may produce a long-term complete remission of LGLL. The paradoxical efficacy of this specific anti–B-cell therapy on a T-cell monoclonal disease suggests that, in some cases, T-cell LGLL may be a reactive manifestation of chronic autoantigen stimulation rather than a true malignancy. Studies are warranted to assess our preliminary findings.

**Acknowledgments**

The authors thank the local tumor tissue biobank “Tumorothèque de Brest” and the Brest Biological Resources Center (“CRB Santé de Brest”) for providing the frozen bone marrow and blood samples.

**Authorship**

**Contribution:** D.C., V.D.-P., S.J.-J., T.M., V.U., C.B., N.D.-G., and A.S. participated in the management of these two patients; D.C. and A.S. wrote the manuscript; and D.C., V.D.-P., S.J.-J., T.M., V.U., C.B., N.D.-G., and A.S. revised the manuscript.

**Conflict-of-interest disclosure:** The authors declare no competing financial interests.

**Correspondence:** Divi Cornec, Service de Rhumatologie, Hôpital de la Cavale Blanche, BP 824, F 29609 Brest cedex, France; e-mail: divi.cornec@chu-brest.fr.

**References**


